Pharmacotherapy of Psychological Disorders Using Psychedelic Drugs: A Treatise for Psychiatrists

After decades of research restrictions, psychedelics are being reexamined as potential treatments for difficult-to-treat mental illnesses. They are generally considered physically safe and rarely lead to addiction. The Controlled Substances Act of 1970 classified psychedelics as Schedule I drugs. This review highlights the prospective use of psilocybin, LSD, MDMA, and ayahuasca for conditions such as treatment-resistant depression, post-traumatic stress disorder, end-of-life anxiety, and substance misuse disorders. Evidence from both animal and human studies suggests these substances may offer revolutionary treatments, but their history and potential for abuse require careful regulation to ensure they are used as effective medical treatments rather than drugs of abuse.

Study at a glance

Abstract

: Psychedelics are currently being examined once more as potential remedies for untreatable biological illnesses after decades of research problems. They are frequently regarded to be physically safe and do not frequently lead to dependency or addiction. The use of psychedelic substances in the treatment of mental illness and the adoption of the Substance Act of 1970 has classified psychedelic drugs as Schedule I. The major objective of this review is to highlight the prospective use of specific psychedelic medicines, such as psilocybin, LSD, MDMA, and ayahuasca, in the treatment of various psychiatric conditions, such as treatment-resistant depression, post-traumatic traumatic stress, end-of-life anxiety, and substance misuse disorders. As documented from both animal and human studies, in addition, there will be a study of the effectiveness and safety. The body of research suggests that psychedelics may one day offer revolutionary treatments for mental diseases, contrary to conventional therapy. However, given their distinctive histories and a high potential for abuse with widespread distribution, more care and effort must be given to protect their use as efficient medical treatments instead of drugs of abuse.